FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1877806169> ?p ?o ?g. }

• W1877806169 endingPage "487.e9" @default.
• W1877806169 startingPage "477" @default.
• W1877806169 abstract "Etrolizumab is a humanized monoclonal antibody against the β7 integrin subunit that has shown efficacy vs placebo in patients with moderate to severely active ulcerative colitis (UC). Patients with colon tissues that expressed high levels of the integrin αE gene (ITGAE) appeared to have the best response. We compared differences in colonic expression of ITGAE and other genes between patients who achieved clinical remission with etrolizumab vs those who did.We performed a retrospective analysis of data collected from 110 patients with UC who participated in a phase 2 placebo-controlled trial of etrolizumab, as well as from 21 patients with UC or without inflammatory bowel disease (controls) enrolled in an observational study at a separate site. Colon biopsies were collected from patients in both studies and analyzed by immunohistochemistry and gene expression profiling. Mononuclear cells were isolated and analyzed by flow cytometry. We identified biomarkers associated with response to etrolizumab. In the placebo-controlled trial, clinical remission was defined as total Mayo Clinic Score ≤2, with no individual subscore >1, and mucosal healing was defined as endoscopic score ≤1.Colon tissues collected at baseline from patients who had a clinical response to etrolizumab expressed higher levels of T-cell-associated genes than patients who did not respond (P < .05). Colonic CD4(+) integrin αE(+) cells from patients with UC expressed higher levels of granzyme A messenger RNA (GZMA mRNA) than CD4(+) αE(-) cells (P < .0001); granzyme A and integrin αE protein were detected in the same cells. Of patients receiving 100 mg etrolizumab, a higher proportion of those with high levels of GZMA mRNA (41%) or ITGAE mRNA (38%) than those with low levels of GZMA (6%) or ITGAE mRNA (13%) achieved clinical remission (P < .05) and mucosal healing (41% GZMA(high) vs 19% GZMA(low) and 44% ITGAE(high) vs 19% ITGAE(low)). Compared with ITGAE(low) and GZMA(low) patients, patients with ITGAE(high) and GZMA(high) had higher baseline numbers of epithelial crypt-associated integrin αE(+) cells (P < .01 for both), but a smaller number of crypt-associated integrin αE(+) cells after etrolizumab treatment (P < .05 for both). After 10 weeks of etrolizumab treatment, expression of genes associated with T-cell activation and genes encoding inflammatory cytokines decreased by 40%-80% from baseline (P < .05) in patients with colon tissues expressing high levels of GZMA at baseline.Levels of GZMA and ITGAE mRNAs in colon tissues can identify patients with UC who are most likely to benefit from etrolizumab; expression levels decrease with etrolizumab administration in biomarker(high) patients. Larger, prospective studies of markers are needed to assess their clinical value." @default.
• W1877806169 created "2016-06-24" @default.
• W1877806169 creator A5002942657 @default.
• W1877806169 creator A5003632939 @default.
• W1877806169 creator A5012913402 @default.
• W1877806169 creator A5019474609 @default.
• W1877806169 creator A5029273084 @default.
• W1877806169 creator A5031136418 @default.
• W1877806169 creator A5032417574 @default.
• W1877806169 creator A5036281306 @default.
• W1877806169 creator A5037536713 @default.
• W1877806169 creator A5040354010 @default.
• W1877806169 creator A5042526092 @default.
• W1877806169 creator A5047810971 @default.
• W1877806169 creator A5048464948 @default.
• W1877806169 creator A5055428095 @default.
• W1877806169 creator A5059435501 @default.
• W1877806169 creator A5061810729 @default.
• W1877806169 creator A5074037618 @default.
• W1877806169 creator A5077985931 @default.
• W1877806169 creator A5080216888 @default.
• W1877806169 creator A5082555885 @default.
• W1877806169 creator A5083726032 @default.
• W1877806169 creator A5087152539 @default.
• W1877806169 creator A5087930883 @default.
• W1877806169 creator A5090249459 @default.
• W1877806169 date "2016-02-01" @default.
• W1877806169 modified "2023-10-17" @default.
• W1877806169 title "Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis" @default.
• W1877806169 cites W1492282569 @default.
• W1877806169 cites W180136612 @default.
• W1877806169 cites W1871793426 @default.
• W1877806169 cites W1895620535 @default.
• W1877806169 cites W1981700839 @default.
• W1877806169 cites W1990388100 @default.
• W1877806169 cites W1995275059 @default.
• W1877806169 cites W1995900768 @default.
• W1877806169 cites W1998140184 @default.
• W1877806169 cites W2005575963 @default.
• W1877806169 cites W2021667091 @default.
• W1877806169 cites W2024398728 @default.
• W1877806169 cites W2035419373 @default.
• W1877806169 cites W2051465794 @default.
• W1877806169 cites W2061012867 @default.
• W1877806169 cites W2082595913 @default.
• W1877806169 cites W2096441981 @default.
• W1877806169 cites W2096515408 @default.
• W1877806169 cites W2105022693 @default.
• W1877806169 cites W2111210489 @default.
• W1877806169 cites W2115180633 @default.
• W1877806169 cites W2131781891 @default.
• W1877806169 cites W2144642115 @default.
• W1877806169 cites W2146080550 @default.
• W1877806169 cites W2156375860 @default.
• W1877806169 cites W2162805528 @default.
• W1877806169 cites W2163007870 @default.
• W1877806169 cites W2165290386 @default.
• W1877806169 cites W2168036150 @default.
• W1877806169 cites W2168663010 @default.
• W1877806169 cites W2171777753 @default.
• W1877806169 cites W2179438025 @default.
• W1877806169 cites W2321205867 @default.
• W1877806169 cites W4210972027 @default.
• W1877806169 doi "https://doi.org/10.1053/j.gastro.2015.10.041" @default.
• W1877806169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26522261" @default.
• W1877806169 hasPublicationYear "2016" @default.
• W1877806169 type Work @default.
• W1877806169 sameAs 1877806169 @default.
• W1877806169 citedByCount "125" @default.
• W1877806169 countsByYear W18778061692015 @default.
• W1877806169 countsByYear W18778061692016 @default.
• W1877806169 countsByYear W18778061692017 @default.
• W1877806169 countsByYear W18778061692018 @default.
• W1877806169 countsByYear W18778061692019 @default.
• W1877806169 countsByYear W18778061692020 @default.
• W1877806169 countsByYear W18778061692021 @default.
• W1877806169 countsByYear W18778061692022 @default.
• W1877806169 countsByYear W18778061692023 @default.
• W1877806169 crossrefType "journal-article" @default.
• W1877806169 hasAuthorship W1877806169A5002942657 @default.
• W1877806169 hasAuthorship W1877806169A5003632939 @default.
• W1877806169 hasAuthorship W1877806169A5012913402 @default.
• W1877806169 hasAuthorship W1877806169A5019474609 @default.
• W1877806169 hasAuthorship W1877806169A5029273084 @default.
• W1877806169 hasAuthorship W1877806169A5031136418 @default.
• W1877806169 hasAuthorship W1877806169A5032417574 @default.
• W1877806169 hasAuthorship W1877806169A5036281306 @default.
• W1877806169 hasAuthorship W1877806169A5037536713 @default.
• W1877806169 hasAuthorship W1877806169A5040354010 @default.
• W1877806169 hasAuthorship W1877806169A5042526092 @default.
• W1877806169 hasAuthorship W1877806169A5047810971 @default.
• W1877806169 hasAuthorship W1877806169A5048464948 @default.
• W1877806169 hasAuthorship W1877806169A5055428095 @default.
• W1877806169 hasAuthorship W1877806169A5059435501 @default.
• W1877806169 hasAuthorship W1877806169A5061810729 @default.
• W1877806169 hasAuthorship W1877806169A5074037618 @default.
• W1877806169 hasAuthorship W1877806169A5077985931 @default.
• W1877806169 hasAuthorship W1877806169A5080216888 @default.

• next